CSL and Arcturus Therapeutics announced that the European Commission has approved KOSTAIVE (ARCT-154), a self-amplifying mRNA COVID-19 vaccine, for adults. This marks the first approval of an sa-mRNA COVID-19 vaccine by the European Commission, following its existing use in Japan. The approval hinges on positive clinical trial data demonstrating superior immunogenicity and antibody persistence compared to traditional mRNA vaccines.
This approval is a critical development for public health, particularly as COVID-19 continues to evolve. KOSTAIVE’s enhanced immune response and extended protection duration could offer a more robust defense against emerging variants, potentially reducing the frequency of booster shots and providing more durable protection for vulnerable populations. This could also lead to improved vaccine uptake, as individuals may be more inclined to receive a vaccine offering longer-lasting protection.
Clinical trials of KOSTAIVE showed stronger immune responses and antibody persistence for up to 12 months compared to existing mRNA vaccines. The technology behind KOSTAIVE, self-amplifying mRNA, instructs the body to produce more mRNA and protein, thus amplifying the immune response. The European Commission’s centralized authorization makes KOSTAIVE valid across all EU member states and EEA countries.
This approval paves the way for broader access to a potentially more effective COVID-19 vaccine in Europe. While CSL is currently refining KOSTAIVE’s formulation, the approval represents a significant step forward in combating the ongoing pandemic and underscores the potential of sa-mRNA technology in vaccine development. The success of KOSTAIVE could encourage further research and development into sa-mRNA vaccines for other infectious diseases, potentially revolutionizing the vaccine landscape.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
